Lung and colorectal cancer screening and health economic evaluation: a population-based multicenter randomized controlled trial
Ontology highlight
ABSTRACT:
DISEASE(S): Lung Cancer, Pulmonary Nodule, Colorectal Cancer, Colorectal Precancerous Lesions
PROVIDER: 2682608 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
Similar Datasets
Project description:Lung cancer is the leading cause of cancer mortality and early detection is the key to improve survival. However, there are no reliable blood-based tests currently available for early-stage lung cancer diagnosis. Here, we performed single-cell RNA sequencing of early-stage lung cancer and found lipid metabolism was broadly dysregulated in different cell types and glycerophospholipid metabolism is the most significantly altered lipid metabolism-related pathway. Untargeted lipidomics were detected in an exploratory cohort of 311 participants. Through support vector machine algorithm-based and mass spectrum-based feature selection, we have identified nine lipids as the most important detection features and developed a LC-MS-based targeted assay utilizing multiple reaction monitoring. This target assay achieved 100.00% specificity on an independent validation cohort. In a hospital-based lung cancer screening cohort of 1036 participants examined by low dose CT and a prospective clinical cohort containing 109 participants, this assay reached over 90.00% sensitivity and 92.00% specificity. Accordingly, matrix-assisted laser desorption/ionization-mass spectrometry imaging assay confirmed the selected lipids were differentially expressed in early-stage lung cancer tissues in situ. Thus, this method, designated as Lung Cancer Artificial Intelligence Detector (LCAID), may be used for early detection of lung cancer or large-scale screening of high-risk populations in cancer prevention.
2021-11-05 | MSV000088324 | MassIVE
Project description:We investigated whether biomarker analysis in endobronchial epithelial lining fluid (ELF) collected by bronchoscopic microsampling may be useful for a definitive preoperative diagnosis. Therefore we compared ELF samples close to nodule and from the contralateral site from patients with malignant or benign diagnosis. ELF samples have been derived from early stage NSCLC patients and controls. Wilcox Test was performed to identify differentially expressed genes associated to a malignant diagnosis. key words: disease subtype analysis
2011-12-31 | E-GEOD-27553 | biostudies-arrayexpress
Project description:We investigated whether biomarker analysis in endobronchial epithelial lining fluid (ELF) collected by bronchoscopic microsampling may be useful for a definitive preoperative diagnosis. Therefore we compared ELF samples close to nodule and from the contralateral site from patients with malignant or benign diagnosis. ELF samples have been derived from early stage NSCLC patients and controls. LIMMA analysis was performed to identify differentially expressed genes associated to a malignant diagnosis. keywords: disease subtype analysis
2011-12-31 | E-GEOD-27489 | biostudies-arrayexpress
Project description:Lung cancer is the leading cause of cancer mortality and early detection is the key to improve survival. However, there are no reliable blood-based tests currently available for early-stage lung cancer diagnosis. Here, we performed single-cell RNA sequencing of early-stage lung cancer and found lipid metabolism was broadly dysregulated in different cell types and glycerophospholipid metabolism is the most significantly altered lipid metabolism-related pathway. Untargeted lipidomics were detected in an exploratory cohort of 311 participants. Through support vector machine algorithm-based and mass spectrum-based feature selection, we have identified nine lipids as the most important detection features and developed a LC-MS-based targeted assay utilizing multiple reaction monitoring. This target assay achieved 100.00% specificity on an independent validation cohort. In a hospital-based lung cancer screening cohort of 1036 participants examined by low dose CT and a prospective clinical cohort containing 109 participants, this assay reached over 90.00% sensitivity and 92.00% specificity. Accordingly, matrix-assisted laser desorption/ionization-mass spectrometry imaging assay confirmed the selected lipids were differentially expressed in early-stage lung cancer tissues in situ. Thus, this method, designated as Lung Cancer Artificial Intelligence Detector (LCAID), may be used for early detection of lung cancer or large-scale screening of high-risk populations in cancer prevention.
2021-11-05 | MSV000088324 | GNPS
Project description:Interventions: Group A:Annual LDCT (5 rounds) and colonoscopy for any year (first year is recommended);Group B:Biennial LDCT (3 rounds) and annual FIT (5 rounds), those who have FIT positive results will undertake colonoscopy;Group C:To inform the participants of high risk of lung cancer and recommend them to undertake lung cancer screening in other regular medical institutions; To recommend colonoscopy for any year (first year is recommended), and those who are unwilling to undertake colonoscopy will receive FIT screening (5 rounds), those
Primary outcome(s): lung cancer mortality;colorectal cancer mortality
Study Design: Parallel
| 2686263 | ecrin-mdr-crc
Project description:Lung cancer remains the greatest cause of cancer related deaths and Low Dosage Computerized Tomography (LDCT) has been shown to improve early detection of lung cancer and survival rate of high risk individuals. However, such imaging is limited by high rates of false positivity leading to unnecessary patient anxiety and invasive procedures. Complementary blood biomarkers could increase the accuracy of early detection. We conducted next generation sequencing on extracellular vesicles (EVs) in plasma in cohorts of smoking and age matched individuals with surgically documented solitary lung nodules that were either adenocarcinomas or benign granulomas, and identified a glucose regulation gene TKTL1 as the most upregulated mRNA between the two cohorts. Together with a previously identified gene, TTF1, we designed molecular beacons and used a novel and yet facile tethered lipoplex nanoparticle (TLN) nanochip to assess their performance in lung cancer detection.
2020-12-31 | GSE71661 | GEO
Project description:Early diagnosis of cancer has been shown to substantially improve 5-year survival rates for many cancer types. With current methodologies early diagnosis has proven difficult for cancers of deep tissues, such as the pancreas and lung. However, whole peripheral blood has been demonstrated to be a promising non-invasive surrogate tissue for the detection of many types of cancer. Blood samples were collected in EDTA blood collection tubes from 2,485 human volunteers and gene expression profiled with the goal to develop a classification model that differentiations patients with cancer from those without cancer.
2024-08-31 | GSE203024 | GEO
Project description:Lung cancer is the most common cause of death from cancer worldwide, largely due to frequent late diagnosis. Thus, there is the urgent need to develop new approaches to improve theearly detection of lung cancer, which would greatly affect patient survival. The quantitative protein expression profiles of microvesicles isolated from sera from 46 lung cancer patients and 41 high-risk non-cancer subjects were obtained using a mass spectrometry method based on library matching. We identified 33 differentially expressed proteins that allow discriminating the two groups. Based on serum protein expression profiles, we built a machine learning algorithm , which highlighted a decrease in the levels of Arysulfatase A (ARSA) as the most discriminating factor found in tumors. Our study identified a signature able to discriminate with high specificity and selectivity early lung cancer patients from high-risk healthy subjects. Among the differentially expressed proteins, ARSA emerged as the most promising biomarker for lung cancer early diagnosis.
2023-02-13 | PXD034221 | Pride
Project description:The paper describes a model on the detection of cancer based on cancer and immune biomarkers.
Created by COPASI 4.25 (Build 207)
This model is described in the article:
Improving cancer detection through combinations of cancer and immune biomarkers: a modelling approach
Raluca Eftimie and and Esraa Hassanein
J Transl Med (2018) 16:73
Abstract:
Background: Early cancer diagnosis is one of the most important challenges of cancer research, since in many can- cers it can lead to cure for patients with early stage diseases. For epithelial ovarian cancer (which is the leading cause of death among gynaecologic malignancies) the classical detection approach is based on measurements of CA-125 biomarker. However, the poor sensitivity and specificity of this biomarker impacts the detection of early-stage cancers.
Methods: Here we use a computational approach to investigate the effect of combining multiple biomarkers for ovarian cancer (e.g., CA-125 and IL-7), to improve early cancer detection.
Results: We show that this combined biomarkers approach could lead indeed to earlier cancer detection. However, the immune response (which influences the level of secreted IL-7 biomarker) plays an important role in improving and/or delaying cancer detection. Moreover, the detection level of IL-7 immune biomarker could be in a range that would not allow to distinguish between a healthy state and a cancerous state. In this case, the construction of solu- tion diagrams in the space generated by the IL-7 and CA-125 biomarkers could allow us predict the long-term evolu- tion of cancer biomarkers, thus allowing us to make predictions on cancer detection times.
Conclusions: Combining cancer and immune biomarkers could improve cancer detection times, and any predic- tions that could be made (at least through the use of CA-125/IL-7 biomarkers) are patient specific.
Keywords: Ovarian cancer, Mathematical model, CA-125 biomarker, IL-7 biomarker, Cancer detection times
This model is hosted on BioModels Database and identified by: MODEL1907050002.
To cite BioModels Database, please use: BioModels Database: An enhanced, curated and annotated resource for published quantitative kinetic models.
To the extent possible under law, all copyright and related or neighbouring rights to this encoded model have been dedicated to the public domain worldwide.
Please refer to CC0 Public Domain Dedication for more information.
2024-09-02 | BIOMD0000000741 | BioModels